OncoNext™ Risk Brain is a diagnostic test, developed by GENOMA Group, which allows you to perform a multiple genetic analysis to assess the predisposition to the development of brain cancer. The test, therefore, allows you to identify patients at risk of developing this neoplasia by analyzing their DNA.
OncoNext ™ Risk OncoScreening Complete is a diagnostic test, developed by GENOMA Group, which allows you to perform a multiple genetic analysis to assess the predisposition to hereditary cancers, including: Breast Cancer, Ovarian / Uterus Cancer, Colorectal Cancer, Stomach Cancer, Pancreatic Cancer, Prostate Cancer, Skin Cancer (Melanoma), Brain Cancer, Kidney Cancer and Pheochromocytoma / Paraganglioma. […]
Eurofins Genoma Group’s OncoNext ™ Liquid genetic tests were designed to study somatic mutations of circulating tumor DNA (ctDNA) in peripheral blood in patients with cancer or at high risk of cancer. The study of ctDNA, also called liquid biopsy, is the most innovative tool that the oncologist can use today. Thanks the OncoNext ™ […]